The SGLT2i have a mechanism of action not linked to insulin secretion, which makes the detrimental occurrence of hypoglycemia less likely compared to other classes of anti-diabetic drugs and also allows the achievement of steady levels of blood glucose. This evidence concerns the gene INS and Hypoglycemia.